Intravitreal aflibercept in treatment-resistant pigment epithelial detachment.
The purpose of the study was to assess the efficacy and safety of transition from ranibizumab to aflibercept intravitreal injections in treatment-resistant retinal pigment epithelial detachment (PED). The data of intravitreal ranibizumab treatment-resistant patients who have been switched to aflibercept treatment were reviewed retrospectively. After three monthly injections, bimonthly regimen was performed. The changes of PED height and radius, and the best-corrected visual acuity (BCVA) were analyzed retrospectively. Mean baseline PED height decreased from 297 ± 151 to 122 ± 42 µm at month 12 (P = 0.0007). Mean baseline PED radius decreased from 2371 ± 882 to 1859 ± 779 µm at month 12 (P = 0.0007). No complete PED resolution occurred in any of the patients at the end of the 12 months. Baseline BCVA improved from 0.63 ± 0.21 to 0.43 ± 0.17 logMar at month 12 (P = 0.0049). Mean BCVA gain was 1.4 decimal chart lines (7 letters) at month 12. Switching to aflibercept seems to have promising functional and anatomical outcomes with a reasonable complication rate in treatment-resistant PED.